Nura Bio Secures $74M Series B to Advance ALS Drug
San Francisco-based Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, has announced the completion of a $73.8... Read More
The post Nura Bio Secures $74M Series B to Advance ALS Drug appeared first on citybiz.